focus -WSS

focus

author：knowledge 2025-10-08 16:02:30 - browse：8

empty test tubes in the hand. -- first opinion coverage from STAT — Adobe

The Food and Drug Administration on Friday announced its intention to start regulating tests developed in laboratories — closing the “Theranos loophole” that has allowed inaccurate tests to slip through the cracks.

Lawmakers came close last year to passing a bill that would have given the FDA this authority, but it was ultimately rejected by Republicans who sympathized with the labs in academic medical centers and hospitals that opposed the provision. FDA Commissioner Robert Califf said at the time that if the bill failed, the agency would take matters into its own hands.

The proposed rule fulfills that promise, adding lab diagnostics to the list of devices that fall under FDA enforcement — a move that patient groups and non-lab test makers support, and that laboratories are likely to dispute. When the FDA started regulating medical devices in 1976, lab-developed tests were simple and offered mostly to local patient populations. The agency generally allowed labs to use these tests without submitting proof of their efficacy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： ReNAgade cuts staff seven months after raising $300 million

leisure time

WSS

Trump surgeon general acknowledges mistakes during Covid

Why Novartis is changing the name of its research labs

UnitedHealth’s Optum accused of antitrust violations in California

30 years of 'Listening to Prozac'

Rep. Raul Ruiz on the physician shortage and more

Amazon on where the company's health care bets are headed next

focus

focus

entertainment

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Peter Hotez and the public health issue of online harassment

The (many) problems with a new study criticizing cancer screening

Psychedelics group wrestles with new pharma identity

Rep. Raul Ruiz on the physician shortage and more

Dobbs anniversary: the lost opportunity of abortion as health care

What American doctors can learn from their Israeli counterparts

Trump demands the U.S. pay no more for drugs than other countries … again

The 10 drugs up first for Medicare price negotiation

focus

With clinical trial data readouts, here's how to spot spin

J&J to emphasize cancer drugs, stop much of its vaccine research

As biotech industry slumps, bioscience job market is upside down

NIH nominee Bertagnolli will get October confirmation hearing

Advances in CAR

What American doctors can learn from their Israeli counterparts

hotspot

entertainment

leisure time

entertainment